BioXcel Therapeutics, Inc. Gain (Loss) on Derivative Instruments, Net, Pretax
BioXcel Therapeutics, Inc. (BTAI) reported Gain (Loss) on Derivative Instruments, Net, Pretax of -$3.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2026-03-27
- BioXcel Therapeutics, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2025 was -$3.50M, a 117.37% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2024 was $20.18M, a 4507.53% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2023 was $438.00K.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|
| 2025-12-31 | -$3.50M 10-K · filed 2026-03-27 |
| 2024-12-31 | $20.18M 10-K · filed 2026-03-27 |
| 2023-12-31 | $438.00K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |